Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2016-01-11 Regulatory Filings
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
Immediate Report
Regulatory Filings Classification · 95% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority and the Tel Aviv Stock Exchange, referencing 'Regulation 4 of the Securities Regulations (Periodic and Immediate Reports of Foreign Corporation) 5761-2000'. The core content announces the 'submittion of a full protocol for advanced stage clinical trial... to Yeda Research and Development Company Ltd.' and explicitly names an attached PDF file ('XTLB_6K_Yeda_Milestone_isa.pdf'). Since this is a short announcement (1793 chars) detailing the publication of specific information rather than being the full report itself, it fits the description of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given the specific nature of reporting a milestone/protocol submission, RNS (Regulatory Filings) is the most appropriate general category for miscellaneous, immediate regulatory disclosures that don't fit the other specific types (like ER, 10-K, or DIV).
2016-01-11 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by XTL Biopharmaceuticals Ltd., a foreign private issuer. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Form 20-F or 40-F. The content includes a press release about submission of a clinical trial protocol, company background, and forward-looking statements. There are no financial statements or detailed financial analysis present. The document is a regulatory filing to inform the market about a corporate development rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-01-11 English
Other Report or Announcement
Capital/Financing Update Classification · 100% confidence The document is a Form F-1 registration statement filed with the U.S. Securities and Exchange Commission (SEC) by XTL Biopharmaceuticals Ltd. The Form F-1 is used by foreign private issuers to register securities for public offering in the U.S. It includes detailed information about the company, the securities being offered, risk factors, management discussion and analysis, financial data, and other disclosures necessary for an initial public offering or other securities offering. This is not an annual report, earnings release, or any other type of periodic report, but a registration statement prospectus for a securities offering. According to the filing definitions, this type of document corresponds to a Capital/Financing Update (CAP) as it relates to company fundraising and securities registration for public offering.
2016-01-03 Hebrew (modern)
Other Report or Announcement
Report Publication Announcement Classification · 98% confidence The document is very short (1660 characters) and explicitly states, "Attached hereto is a report on *Form F-1 Submission*" along with a filename. This structure indicates that the document itself is an announcement about the publication of another filing (Form F-1 Submission), rather than the full content of that filing. According to Rule 2, when a document is short and announces the availability of a report, it should be classified as a Report Publication Announcement (RPA). Although Form F-1 is a registration statement, the context here is an announcement made via the Israeli regulatory system (ISA/TASE) about this attachment.
2016-01-03 English
FORM F-1
Capital/Financing Update Classification · 95% confidence The document is a Form F-1 registration statement filed with the U.S. Securities and Exchange Commission (SEC). It is a registration document used by companies planning an initial public offering (IPO) or other securities offering to register their securities with the SEC. The text includes details such as the registration fee, offering price, underwriting discounts, and a prospectus summary. It also contains extensive business and financial information typical of a registration statement. This type of filing is related to capital raising activities and is not an annual report, earnings release, or other types of filings listed. The closest matching category is Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. Therefore, the document should be classified as CAP with high confidence.
2015-12-31 English
Immediate Report
Regulatory Filings
2015-12-29 Hebrew (modern)

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.